The Technion’s story has been intertwined with Israel’s for more than a century, from laying the foundations for a new nation to shaping its future.
Step inside Israeli innovation at the David and Janet Polak Visitors Center. Experience our 360° immersive movie and tech exhibition. Open to individuals and groups.
Learn More
Emma Pierson, assistant professor of computer science at the Jacobs Technion-Cornell Institute at Cornell Tech, is one of 19 researchers who have been awarded an AI2050 Early Career Fellowship from Schmidt Sciences for her work seeking to use artificial intelligence to promote equity. Pierson, also a computer science field member at the Cornell Ann S. Bowers College of Computing and Information Science, is working on “Using LLMs (large-language models) for Health Equity.” As a member of the second cohort of Early Career Fellows, she will receive $300,000 over two years from Schmidt Sciences to further her work related to artificial intelligence and health care.
Hours in surgery, weeks in hospitals and months of recuperation – or a five-minute procedure under local anesthesia and straight back home with no side effects. That’s the difference that AI (artificial intelligence) developed in Israel will now be making for patients diagnosed with liver cancer. Techsomed, a medical imaging startup, allows physicians for the first time to see exactly what’s happening in real time while they destroy (or ablate) a tumor using targeted heat through a needle. Thermal ablation therapy, a minimally invasive procedure for small tumors, has huge benefits over surgery or chemotherapy for the patients.
Associate Professor Shenhav Shemer from the Technion’s Faculty of Biology has joined the DREAMS team, a European Union-funded project to discover treatments for five rare neuromuscular disorders. DREAMS (Drug REpurposing and Artificial intelligence for Muscular disorderS) will focus on treatments for Duchenne muscular dystrophy, centronuclear myopathy, Emery-Dreifuss muscular dystrophy, Pompe disease, and Danon disease. Approximately 400,000 people worldwide suffer from these diseases. “My group is engaged in various phases of the project, including the key phases of identifying biomarkers and therapeutic targets, assessing the efficacy of molecules as novel drugs to inhibit these targets and address the disease, validating…
To bring a new drug to market costs on average $1.3 billion, according to a recent report in the Journal of the American Medical Association, and takes up to 20 years. These astronomical sums do factor in the billions of dollars and years of research invested in what potentially promising therapies that ultimately lead nowhere, according to David Harel, the co-founder and CEO of CytoReason, an Israeli startup using AI and reams of data on the human body to create computational models of diseases affecting mankind. “Developing new drugs is very, very expensive. And the reason it’s expensive is not only…
By the time Sara Smolley was born, her grandmother was unable to talk to her. She had been diagnosed with early onset Parkinson’s disease at the age of just 40, which stripped her of much of her motor capabilities. “More than anything, it was her speech that was impacted,” says Smolley, the co-founder and VP Partnerships of Voiceitt, an Israeli speech recognition platform for people who have non-standard speech. “Of course, that affected her ability to build a relationship with my brothers and me, as we couldn’t understand what she was saying,” she tells NoCamels. The AI-powered Voiceitt platform is designed…
More than 250,000 Israelis are refugees in their own land, having been evacuated from the north and south of the country due to the Israel-Hamas war in the south and threats from Hezbollah in the north. The Technion is providing many with housing and other services and is offering a one-week robophysics program for outstanding 11th- and 12th-graders who have been displaced. Partnering with Atidim, a nonprofit organization dedicated to providing educational opportunities to bright young people from Israel’s underserved and marginalized communities, 30 high school students participated in a robophysics program created by the Technion’s Andrew and Erna Viterbi…
An Israeli startup that uses artificial intelligence to dub movies and TV shows into different languages has launched the first initiative of its kind to provide fair compensation to voice actors for the use of their voices in AI-powered dubbing and other synthetic voice projects. Deepdub uses proprietary AI to generate synthetic voices that capture the emotion and delivery of the original performances, but in a new language. The technology streamlines the labor-intensive dubbing process and reduces costs, while matching the quality of traditional workflows. Now, the startup’s new Voice Artist Royalty Program will save the submitted audio samples of voice actors in…
American-Israeli startup PhaseV is on a mission to overcome one of the most significant challenges of drug development: the clinical trial phase, the longest and most expensive part of the process. A recent Deloitte report reveals that, on average, a single new drug takes $2.3 billion and seven years to develop. Yet many candidates fail the clinical phase even if the biology works. That makes for a poor return on investment and wasted potential for treating diseases. “The development process for new drugs must therefore be transformed and could be made much more efficient with digital technologies,” the report urges.
Israeli and US medtech companies have teamed up to create a program that uses artificial intelligence to identify patients at high risk for respiratory or pulmonary diseases such as lung cancer. The LungFlag AlgoMarker, which analyzes data from a patient’s electronic health record, is a collaboration between Medial EarlySign, a Hod Hasharon-based company that develops clinical predictive analytics, and Geisinger, an integrated healthcare system from Pennsylvania. Working with Geisinger, Medial EarlySign developed the program to facilitate earlier invention, which is a key feature of the American healthcare provider’s care model as it helps improve clinical outcomes, creates higher patient satisfaction and reduces…
An Israeli startup that uses artificial intelligence to help manage treatment courses for diabetics has received a fifth clearance from the US Food and Drug Administration (FDA) for its endo.digital platform. The new FDA clearance allows DreaMed to expand the scope of its recommended care plans for diabetics on a fixed regimen of insulin doses that are administered via pump or injection. The endo.digital platform provides an automated total care plan for people with diabetes. The company says it is compatible with most devices used by diabetics to monitor their blood glucose levels and to administer insulin.
A data analytics company in Israel is offering its artificial intelligence tools to help predict where and when the country will suffer rocket attacks during the ongoing war with Hamas in the Gaza Strip – even suggesting the optimal time to take a shower without interruption. Sisense which uses machine learning to analyze data for companies, has made its technology available to Israeli government bodies and other institutions during the conflict. Israel has been under continuous rocket fire from Gaza since October 7, when terrorists breached the border fence into Israel, killing 1,400 people and abducting at least 240 more. More…
Despite initial support for Israel and largely universal condemnation of the Hamas attacks on October 7, the number of anti-Semitic incidents, campus protests, and online vitriol against Israel and Jews has skyrocketed. For many, social media has become a battlefield. Enter Zachary Bamberger, an American who immigrated to Israel. The Cornell graduate is currently working toward his master’s in the Technion’s Henry and Marilyn Taub Faculty of Computer Science. When he saw what was happening online, he sprang into action. Using his prodigious talents in machine learning and natural language processing research, he built a large language model (LLM) that…